Blog
RSS FeedPosted by Michael Wonder on 10 Sep 2021
VOR33 granted U.S. FDA fast track designation for AML
9 September 2021 - Vor Biopharma today announced that the U.S. FDA has granted fast track designation to VOR33, the ...
Posted by Michael Wonder on 03 Sep 2021
MSAC publishes agenda for upcoming meeting
3 September 2021 - 12 agenda items for consideration at the 25-26 November 2021 meeting. ...
Posted by Michael Wonder on 02 Sep 2021
CAR-T therapy Kymriah fails to get insurance benefits
2 September 2021 - The first CAR-T therapy, Kymriah (ingredient: tisagenlecleucel), failed to pass the review of a panel at ...
Posted by Michael Wonder on 20 Aug 2021
Bristol Myers Squibb receives European Commission approval for Abecma (idecabtagene vicleucel), the first anti-BCMA CAR T cell therapy for relapsed and refractory multiple myeloma
19 August 2021 - Abecma represents the only cell therapy approved for multiple myeloma. ...
Posted by Michael Wonder on 09 Aug 2021
Quality assurance requirements of the G-BA also apply to new CAR-T cell therapy
5 August 2021 - The Federal Joint Committee (G-BA) today evaluated the new cancer drug with the trade name Tecartus and ...
Posted by Michael Wonder on 05 Aug 2021
Lymphoma patients to benefit from new cancer therapy
5 August 2021 - Australians suffering from a rare type of blood cancer will now have access to a highly specialised ...
Posted by Michael Wonder on 04 Aug 2021
New CAR T-cell therapy option now available in Australia for patients with aggressive blood cancer
5 August 2021 - Eligible patients can now access Yescarta through Peter MacCallum Cancer Centre, Melbourne and Royal Brisbane and Women’s ...
Posted by Michael Wonder on 22 Jul 2021
bluebird bio receives EC approval for Skysona (elivaldogene autotemcel, Lenti-D) gene therapy for patients less than 18 years of age with early cerebral adrenoleukodystrophy without matched sibling donor
21 July 2021 - Skysona is the first and only gene therapy approved in the European Union to treat early CALD. ...
Posted by Michael Wonder on 12 Jul 2021
Leukaemia patients demand reimbursement for Novartis’ Kymriah
12 July 2021 - Korean leukaemia patients have urged the government to provide rapid reimbursement of Kymriah, the first CAR-T ...
Posted by Michael Wonder on 11 Jul 2021
NICE publishes draft guidance on the use of Libmeldy
9 July 2021 - OTL-200 (Libmeldy) is a gene therapy medicinal product that expresses the human ARSA gene. ...
Posted by Michael Wonder on 30 Jun 2021
Allogene Therapeutics granted FDA fast track designation for ALLO-605, the first TurboCAR T Cell therapy, for the treatment of relapsed/refractory multiple myeloma
30 June 2021 - TurboCAR technology provides selective, programmable cytokine signaling designed to improve function and potency of AlloCAR T cells. ...
Posted by Michael Wonder on 27 Jun 2021
Bristol Myers Squibb receives positive CHMP opinion for anti-BCMA CAR T cell therapy Abecma (idecabtagene vicleucel) for relapsed and refractory multiple myeloma
25 June 2021 - Recommendation for approval based on results from pivotal KarMMa study. ...
Posted by Michael Wonder on 24 Jun 2021
China's first CAR-T cell therapy approved Fosun Kite axicabtagene ciloleucel (FKC876)
24 June 2021 - The first CAR-T cell therapy approved by NMPA: opening a new era of cell therapy in China. ...
Posted by Michael Wonder on 15 Jun 2021
FDA approves StrataGraft for the treatment of adults with thermal burns
15 June 2021 - Today, the U.S. FDA approved StrataGraft for the treatment of adult patients with thermal burns containing intact ...
Posted by Michael Wonder on 01 Jun 2021
Health Canada approves Abecma (idecabtagene vicleucel), the first and only anti-BCMA CAR T cell therapy for relapsed and refractory multiple myeloma
31 May 2021 - Abecma is the first personalised cell therapy available to Canadian patients for the treatment of adults ...